Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Johnson & Johnson | NBTXR3 - (NANORAY-312) | Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) | Phase 3 | Ongoing | Intratumoral | Oncology |
| Johnson & Johnson | Milvexian - (Librexia STROKE) | Stroke prevention in patients after an acute ischemic stroke or high-risk transient ischemic attack | Phase 3 | Ongoing | Oral | Neurology |
| Johnson & Johnson | Milvexian - (Librexia AF) | Prevention of stroke in patients with atrial fibrillation | Phase 3 | Ongoing | Oral | Cardiology |
| Johnson & Johnson | CAPLYTA (lumateperone) - (Study 501) | Major depressive disorder (MDD) | Phase 3 | Data Released | Oral | Psychiatric |
| Johnson & Johnson | IMBRUVICA (ibrutinib) | Diffuse large B-cell lymphoma (DLBCL) | Phase 3 | Trial Discontinued | oral | Oncology |
| Johnson & Johnson | Ad26.COV2.S - Sisonke Study | Booster shot COVID-19 | Phase 3 | Intramuscular | COVID-19 | |
| Johnson & Johnson | HVTN 706/HPX3002 (Mosaico) | HIV in MSM and Transgender | Phase 3 | Intramuscular | Anti-HIV | |
| Johnson & Johnson | ZYTIGA (abiraterone acetate) - (PEACE1) | Prostate Cancer | Phase 3 | Oral | Oncology |
